Epoprostenol and Pulmonary Arterial Hypertension: 20 years of Clinical Experience

Overview

Journal Eur Respir Rev

Specialty Pulmonary Medicine

Date 2017 Jan 19

PMID 28096285

Citations 39

Authors

Olivier Sitbon

Anton Vonk Noordegraaf

Affiliations

Soon will be listed here.

Abstract

Epoprostenol was the first therapy to be approved for the treatment of pulmonary arterial hypertension (PAH). In the 20 years since the introduction of this prostacyclin analogue, the outlook for patients with PAH has improved, with survival rates now double those from the era before the development of disease-specific treatments. Today, there are a large amount of data on the clinical role of prostacyclin treatments and a body of evidence attesting the efficacy of epoprostenol in improving exercise capacity, key haemodynamic parameters and PAH symptoms, as well as in reducing mortality. The place of epoprostenol in the therapeutic management of PAH continues to evolve, with the development of new formulations and use in combination with other drug classes. In this review, we provide a historical perspective on the first 20 years of epoprostenol, a therapy that led to evidence-based study of PAH-specific treatments and the subsequent expansion of treatment options for PAH.

Citing Articles

Pulmonary vascular manifestations of hereditary haemorrhagic telangiectasia.

Cullivan S, Kevane B, McCullagh B, OConnor T, Condliffe R, Gaine S Pulm Circ. 2024; 14(4):e70007.

PMID: 39588537 PMC: 11586239. DOI: 10.1002/pul2.70007.

Parenteral prostacyclin utilization in patients with pulmonary arterial hypertension in the intermediate-risk strata: a retrospective chart review and cross-sectional survey.

Vaidya A, Sketch M, Broderick M, Shlobin O BMC Pulm Med. 2024; 24(1):574.

PMID: 39567921 PMC: 11577822. DOI: 10.1186/s12890-024-03388-w.

Survival, morbidity, and quality of life in pulmonary arterial hypertension patients: a systematic review of outcomes reported by population-based observational studies.

Reinders S, Didden E, Ong R Respir Res. 2024; 25(1):373.

PMID: 39415261 PMC: 11481430. DOI: 10.1186/s12931-024-02994-w.

Current Overview of the Biology and Pharmacology in Sugen/Hypoxia-Induced Pulmonary Hypertension in Rats.

Corboz M, Nguyen T, Stautberg A, Cipolla D, Perkins W, Chapman R J Aerosol Med Pulm Drug Deliv. 2024; 37(5):241-283.

PMID: 39388691 PMC: 11502635. DOI: 10.1089/jamp.2024.0016.

Therapeutic Potential of Treprostinil Inhalation Powder for Patients with Pulmonary Arterial Hypertension: Evidence to Date.

Cassady S, Almario J, Ramani G Drug Healthc Patient Saf. 2024; 16:51-59.

PMID: 38855777 PMC: 11162632. DOI: 10.2147/DHPS.S372239.

References

Moncada S, Gryglewski R, Bunting S, Vane J . An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976; 263(5579):663-5. DOI: 10.1038/263663a0. View

Lambert O, Bandilla D, Iyer R, Witchey-Lakshmanan L, Palepu N . Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted. Drug Des Devel Ther. 2012; 6:61-70. PMC: 3340107. DOI: 10.2147/DDDT.S29916. View

Kuhn K, Byrne D, Arbogast P, Doyle T, Loyd J, Robbins I . Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med. 2002; 167(4):580-6. DOI: 10.1164/rccm.200204-333OC. View

Shapiro S, Oudiz R, Cao T, Romano M, Beckmann X, Georgiou D . Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol. 1997; 30(2):343-9. DOI: 10.1016/s0735-1097(97)00187-3. View

Robbins I, Gaine S, Schilz R, Tapson V, Rubin L, Loyd J . Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest. 2000; 117(1):14-8. DOI: 10.1378/chest.117.1.14. View

Hoeper M, Galie N, Simonneau G, Rubin L . New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002; 165(9):1209-16. DOI: 10.1164/rccm.200110-028PP. View

Christman B, McPherson C, Newman J, King G, Bernard G, GROVES B . An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992; 327(2):70-5. DOI: 10.1056/NEJM199207093270202. View

Jacobs W, Boonstra A, Marcus J, Postmus P, Vonk-Noordegraaf A . Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy. J Heart Lung Transplant. 2009; 28(3):280-4. DOI: 10.1016/j.healun.2008.12.003. View

Thenappan T, Shah S, Rich S, Gomberg-Maitland M . A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J. 2007; 30(6):1103-10. DOI: 10.1183/09031936.00042107. View

10.

Humbert M, Sanchez O, Fartoukh M, Jagot J, Le Gall C, Sitbon O . Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur Respir J. 1999; 13(6):1351-6. DOI: 10.1183/09031936.99.13613579. View

11.

Highland K . Pulmonary arterial hypertension. Am J Med Sci. 2008; 335(1):40-5. DOI: 10.1097/MAJ.0b013e31815d2647. View

12.

Stiebellehner L, Petkov V, Vonbank K, Funk G, Schenk P, Ziesche R . Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest. 2003; 123(4):1293-5. DOI: 10.1378/chest.123.4.1293. View

13.

Higenbottam T, Spiegelhalter D, Scott J, Fuster V, Dinh-Xuan A, Caine N . Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br Heart J. 1993; 70(4):366-70. PMC: 1025334. DOI: 10.1136/hrt.70.4.366. View

14.

Kemp K, Savale L, OCallaghan D, Jais X, Montani D, Humbert M . Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. J Heart Lung Transplant. 2011; 31(2):150-8. DOI: 10.1016/j.healun.2011.11.002. View

15.

Farber H, Loscalzo J . Pulmonary arterial hypertension. N Engl J Med. 2004; 351(16):1655-65. DOI: 10.1056/NEJMra035488. View

16.

Nunes H, Humbert M, Sitbon O, Morse J, Deng Z, Knowles J . Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2003; 167(10):1433-9. DOI: 10.1164/rccm.200204-330OC. View

17.

Langleben D, Barst R, Badesch D, GROVES B, Tapson V, Murali S . Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension. Circulation. 1999; 99(25):3266-71. DOI: 10.1161/01.cir.99.25.3266. View

18.

Prins B, Hu R, Nazario B, Pedram A, Frank H, Weber M . Prostaglandin E2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells. J Biol Chem. 1994; 269(16):11938-44. View

19.

Laving A, Khanna A, Rubin L, Ing F, Dohil R, Lavine J . Successful liver transplantation in a child with severe portopulmonary hypertension treated with epoprostenol. J Pediatr Gastroenterol Nutr. 2005; 41(4):466-8. DOI: 10.1097/01.mpg.0000178441.10417.0f. View

20.

Galie N, Seeger W, Naeije R, Simonneau G, Rubin L . Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2004; 43(12 Suppl S):81S-88S. DOI: 10.1016/j.jacc.2004.02.038. View